Arrhythmogenic Cardiomyopathy Clinical Trials

7 recruiting

Arrhythmogenic Cardiomyopathy Trials at a Glance

10 actively recruiting trials for arrhythmogenic cardiomyopathy are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Ann Arbor, Baltimore, and Barcelona. Lead sponsors running arrhythmogenic cardiomyopathy studies include Centro Medico Teknon, Chinese Academy of Medical Sciences, Fuwai Hospital, and Centro Cardiologico Monzino.

Browse arrhythmogenic cardiomyopathy trials by phase

Treatments under study

About Arrhythmogenic Cardiomyopathy Clinical Trials

Looking for clinical trials for Arrhythmogenic Cardiomyopathy? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Arrhythmogenic Cardiomyopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Arrhythmogenic Cardiomyopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Rocket Pharmaceuticals Inc.9 enrolled3 locationsNCT05885412
Recruiting
Phase 2

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Arrhythmogenic CardiomyopathyArrhythmogenic Right Ventricular Cardiomyopathy
Hamilton Health Sciences Corporation120 enrolled17 locationsNCT06174220
Recruiting

The Application of T1 Mapping in Real-World

Hypertrophic Cardiomyopathy (HCM)MyocarditisMyocardial Infarction (MI)+2 more
Chinese Academy of Medical Sciences, Fuwai Hospital2,000 enrolled1 locationNCT07354646
Recruiting
Phase 2

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

Arrhythmogenic Cardiomyopathy
Centro Cardiologico Monzino102 enrolled5 locationsNCT06922994
Recruiting

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

Arrhythmogenic CardiomyopathyPKP2-ACMPKP2-ARVC
Lexeo Therapeutics40 enrolled6 locationsNCT06976606
Recruiting

Cardiovascular Multimodality Imaging Study

CardiomyopathiesSarcoidosisHypertrophic Cardiomyopathy+4 more
Montefiore Medical Center5,000 enrolled1 locationNCT06610019
Recruiting

Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation

CardiomyopathiesHypertrophic Cardiomyopathy (HCM)Sudden Cardiac Death+14 more
IRCCS Azienda Ospedaliero-Universitaria di Bologna700 enrolled3 locationsNCT06813443
Recruiting

Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy

Dilated CardiomyopathyVentricular ArrhythmiaArrhythmogenic Cardiomyopathy+1 more
Centro Medico Teknon500 enrolled4 locationsNCT06730464
Recruiting

Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.

Hypertrophic Cardiomyopathy (HCM)Non-ischemic CardiomyopathyRestrictive Cardiomyopathy+2 more
Scientific Institute San Raffaele15,000 enrolled1 locationNCT06607471
Recruiting

Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy

Arrhythmogenic Cardiomyopathy
First Affiliated Hospital Xi'an Jiaotong University1,500 enrolled1 locationNCT06352307